by David Porter, MD
In this month’s President’s Message, Dr. David Porter highlights the 30th anniversary of ASTCT’s official journal, Transplantation and Cellular Therapy, celebrating its...
by Misty Evans
This spotlight features Misty Evans, DNP, APRN, CPNP-AC, BMTCN, a dedicated leader in transplant and cellular therapy. As an advocate for APPs and ex-officio ASTCT Board member, she shares her...
by Nature
Building on the success of their T-cell receptor-mimic antibody (TCR-m) targeting the signal peptide CG1, scientists applied a similar construct to the development of chimeric antigen receptor...
by Blood
Research confirms the contribution of CD47 upregulation to the development of graft-versus-host disease (GVHD) following allogeneic hematopoietic cell transplantation (allo-HCT) and supports...
by Nature
Evidence suggests that adding both a calcineurin inhibitor (CNI) and mycophenolate mofetil (MMF) to post-transplant cyclophosphamide (PTCy) may help prevent a common complication after HLA-matched...
by Blood Advances
Registry data suggest post-transplant cyclophosphamide (PTCy) is safe and effective for patients with severe aplastic anemia (SAA) who undergo stem cell transplantation (SCT), especially with...